pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Altuviiio
drug
save

efanesoctocog alfa

Marketedupdated 3mo ago
by Bioverativ Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagHemophilia2 co-mentions · 1 sources
  • companyPSI CRO AG1 co-mentions · 1 sources
  • tagCRO/CDMO1 co-mentions · 1 sources
  • drugicosapent ethyl1 co-mentions · 1 sources
  • drugHemophilia A1 co-mentions · 1 sources

all catalysts(1)

phase 1 completion · 1
Apr 30, 2026
phase 1 completion
4mo ago
PSI CRO AG — efanesoctocog alfa (Phase I Trial Completion)
efanesoctocog alfa
→

Trials studying efanesoctocog alfa

  • phase4Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfarecruitingn=250
  • phase3Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfarecruitingn=104
  • phase1Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia Arecruitingn=24
  • —Goal Attainment and Physical Activity in People With Hemophilia Aterminatedn=3
  • phase4A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxisactive not recruitingn=37
  • phase4Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophyrecruitingn=35
  • phase3A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfaactive not recruitingn=93
  • —A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia Aactive not recruitingn=200
more trials →

News(3)

  • Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
    Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
    fiercebiotech · 4d ago
  • Chutes & Ladders—BioNTech brings in Sobi CEO
    After a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…
    fiercebiotech · 8d ago
  • After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
    One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
    fiercebiotech · 11d ago
brand
Altuviiio
generic
efanesoctocog alfa [INN]
indication
Hemophilia A (Factor VIII Deficiency)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?